Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Indian variant

- PMLiVE

AstraZeneca’s Voydeya granted EC approval to treat rare blood disease PNH

The factor D inhibitor has been authorised for use alongside the company’s complement C5 inhibitors

- PMLiVE

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Antimicrobial resistance has been declared by WHO as one of the top ten threats to global health

- PMLiVE

AstraZeneca study reveals increasing number of people impacted by chronic kidney disease

CKD is a progressive condition that affects nearly 850 million people worldwide

- PMLiVE

AstraZeneca shares positive three-year results for Imfinzi combination in biliary tract cancer

Approximately 210,000 people worldwide are diagnosed with the disease every year

- PMLiVE

AstraZeneca’s Fasenra receives FDA approval for paediatric patients with severe asthma

Severe eosinophilic asthma causes inflammation in the lungs and airways of patients

- PMLiVE

Pfizer shares positive late-stage results for RSV vaccine Abrysvo in high-risk adults

There are currently no vaccines approved for use in adults aged 18 to 59 years

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA accelerated approval for solid tumours

The ADC has been authorised to treat adults with unresectable or metastatic HER2-positive tumours

- PMLiVE

AstraZeneca shares positive late-stage results for Imfinzi in small cell lung cancer

Small cell lung cancer accounts for approximately 15% of all lung cancer cases

- PMLiVE

Pfizer’s antibiotic combination receives CHMP recommendation to treat multidrug-resistant infections

Antimicrobial resistance has been declared by WHO as one of the top ten threats to global public health

- PMLiVE

AstraZeneca’s Voydeya granted FDA approval for rare blood disease PNH

Up to 20% of patients treated with C5 inhibitors experience clinically significant extravascular haemolysis

- PMLiVE

FDA grants Invivyd’s Pemgarda emergency use authorisation for COVID-19 prevention

The long-acting monoclonal antibody is authorised for use in adults and adolescents

- PMLiVE

AstraZeneca’s Ultomiris receives FDA approval to treat rare autoimmune disease NMOSD

Neuromyelitis optica spectrum disorder is estimated to affect approximately 6,000 adults in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links